Posted: June 28, 2018
According to the Edelman survey on trust, 77% of people surveyed refused to purchase a product or service because they did not trust the company behind it. Pharma companies are not exactly tops on the trust scale for reasons you can infer yourself—or listen to EP148 with Jennifer Miller on the Good Pharma Scorecard. As with most…Read More
Posted: June 21, 2018
An experienced executive with several years of experience in the pharmaceutical and biotechnology industry, Dr. Soliman has held key positions within medical affairs where he was instrumental in launching a variety of innovative platforms expanding the role of medical affairs across the industry.
Posted: Sept 06, 2018
The ACMA has appointed Dr. Charles Stacey, President and CEO of Accera Pharmaceuticals to its Board of Governors. Dr. Stacey is the President and CEO of Accera, a global clinical stage biotechnology company focused on the development of therapeutics for CNS disease. Prior to joining Accera, he was with Inventages, the Nestlé backed venture capital and private equity group, with $1.5Bn under management. There he led the CNS interest as well as the fund's interest in Asia. Prior to Inventages, Dr. Stacey ran a medical device company and worked for a number of early-stage healthcare companies.
Posted: Aug 30, 2018
The ACMA has appointed two power players to its Board of Governors Bob Oliver and S. Bob Chib.
Bob Oliver, Recent CEO of V ClinBio, former President and CEO of Otsuka Pharmaceuticals, who also serves as Executive Advisor for both Cellix Bio Sciences Inc and Hyalo Technologies, while serving on the Board of Directors for Neurotez Inc., joins the ACMA Board today.
S. Bob Chib, currently serves as the Head of Corporate Strategy, Innovation, and Business Development at Astellas Pharma. Mr. Chib has more than two decades' experience as a senior biopharma executive.
Posted: Aug 21, 2018
The ACMA announces its appointment of Jason Aryeh, Life Sciences Investment Fund Manager and pharmaceutical industry expert, to its board of governors today. Mr. Aryeh brings with him over twenty years of equity investment experience in the life sciences industry. He is the Founder and Managing General Partner of JALAA Equities, LP, a private, activist-oriented, hedge fund focused on the life sciences sector, and has served in this capacity since 1997. Jason Aryeh will play a critical role in helping to expand the mission of the ACMA in the life sciences industry.
Posted: July 10, 2018
The partnership between the ACMA and Council for Continuing Pharmaceutical Education (CCPE) will enable more medical affairs and MSL professionals in Canada to become Board Certified in Medical Affairs via the Board Certified Medical Affairs Specialist Program (BCMAS). The CCPE and ACMA have collaborated to put together a first in class training program tailored for Canadian MSL professionals.
As Opioid Liability Rises, Accreditor Seeks Credential For Pharma's Educators As Specialty Drugs Gain Share, Trump Looks To Curb Prices. ACMA weighs in on the importance of certifying pharmaceutical professionals. ACMA Announces New Partnership with PhactMI a leading medical information provider in the pharmaceutical industry. ACMA now offers CME/CE for the First & Only Professional Board Certification Program for Medical Science Liaisons & Medical Affairs Professionals The ACMA announced today the appointment of Sotirios G. Stergiopoulos MD, MBEE, BCMAS as new President of the ACMA Board of Governors. Michael H. Davidson, MD joins the International Board of Medical Affairs Officers with the Accreditation Council for Medical Affairs (ACMA) The Board Certified Medical Affairs Specialist Program (BCMAS) comes to Rutgers University providing a new path forward for scientific and clinical professionals looking to work within the pharmaceutical industry
Posted: July 17, 2018
Imagine this scenario: a pharmacist makes a recommendation to a physician to either change, or add a medication to a patient’s regimen but the physician does not accept the recommendation since he or she is either unfamiliar with or does not have much experience with the drug and does not feel comfortable prescribing it. Medical affairs helps tear down these barriers so that both physicians and patients have access to scientifically accurate data and other information they need about a medication.....Read More
Four Reasons a Board Certification in Medical Affairs Will Benefit your company [January 25, 2018] Medical Affairs in 2018-What's coming? [January 17, 2018] Medical Affairs Outlook-A look back at 2017 [December 12, 2017] Medical Affairs Career? You're Certifiable! [August 28, 2017 Are you Ready to work.... Doctor? [June 19, 2017] 5 Smart Ways to Increase Medical Affairs Tenure Without Investing Much [March 28, 2017]